BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Puenpatom A, Hull M, McPheeters J, Schwebke K. Treatment Discontinuation, Adherence, and Real-World Effectiveness Among Patients Treated with Ledipasvir/Sofosbuvir in the United States. Infect Dis Ther 2017;6:423-33. [PMID: 28677020 DOI: 10.1007/s40121-017-0163-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Domínguez-domínguez L, Bisbal O, Matarranz M, Lagarde M, Pinar Ó, Hernando A, Lumbreras C, Rubio R, Pulido F. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection. Eur J Clin Microbiol Infect Dis 2019;38:725-34. [DOI: 10.1007/s10096-019-03488-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lazarus JV, Roel E, Elsharkawy AM. Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy. Cold Spring Harb Perspect Med. 2020;10. [PMID: 31570385 DOI: 10.1101/cshperspect.a036913] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 5.5] [Reference Citation Analysis]
3 Sultan A, Bane A, Braimoh G, Debes JD. Treatment of Hepatitis C Genotypes 1 to 5 in Sub-Saharan Africa Using Direct-Acting Antivirals. Am J Trop Med Hyg 2020;103:2083-4. [PMID: 32828136 DOI: 10.4269/ajtmh.20-0367] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Campos Fernández de Sevilla MÁ, Gallego Úbeda M, Tovar Pozo M, García-Cabrera E, Monje García B, Tutau Gómez F, Delgado Téllez de Cepeda L, Iglesias-Peinado I. Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment. Int J Clin Pharm 2019;41:1545-54. [PMID: 31650508 DOI: 10.1007/s11096-019-00917-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
5 Zarębska-Michaluk D, Piekarska A, Jaroszewicz J, Klapaczyński J, Mazur W, Krygier R, Belica-Wdowik T, Baka-Ćwierz B, Janczewska E, Pabjan P, Dobracka B, Lorenc B, Tudrujek-Zdunek M, Tomasiewicz K, Sitko M, Garlicki A, Czauż-Andrzejuk A, Citko J, Dybowska D, Halota W, Pawłowska M, Laurans Ł, Deroń Z, Buczyńska I, Simon K, Białkowska J, Tronina O, Flisiak R. Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis. Adv Med Sci 2020;65:12-7. [PMID: 31841821 DOI: 10.1016/j.advms.2019.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Kwo PY, Puenpatom A, Zhang Z, Hui SL, Kelley AA, Muschi D. Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis. PLoS One 2019;14:e0218759. [PMID: 31437170 DOI: 10.1371/journal.pone.0218759] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Guzman Ramos MI, Manzano-García M, Robustillo-Cortés MLA, Pineda JA, Morillo-Verdugo R. Effect on the adherence to concomitant medications after initiation of treatment with direct-acting antiviral agents against hepatitis C virus. Gastroenterol Hepatol 2020;43:418-25. [PMID: 32279937 DOI: 10.1016/j.gastrohep.2020.02.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Sulkowski M, Luetkemeyer AF, Wyles DL, Martorell C, Muir A, Weisberg I, Gordon SC, McLain R, Huhn G. Impact of a digital medicine programme on hepatitis C treatment adherence and efficacy in adults at high risk for non-adherence. Aliment Pharmacol Ther 2020;51:1384-96. [PMID: 32352586 DOI: 10.1111/apt.15707] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
9 An J, Lee JS, Sharpsten L, Wilson AK, Cao F, Tran JN. Impact of pill burden on adherence to hepatitis C medication. Curr Med Res Opin 2019;35:1937-44. [PMID: 31298592 DOI: 10.1080/03007995.2019.1643160] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
10 DeBose-Scarlett A, Balise R, Kwon D, Vadaparampil S, Chen SX, Schiff ER, Ayala GP, Thomas E. Obstacles to successful treatment of hepatitis C in uninsured patients from a minority population. J Transl Med 2018;16:178. [PMID: 29954391 DOI: 10.1186/s12967-018-1555-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]